Liem G S, Verweij J
Rotterdam Cancer Institute, Daniel den Hoed Kliniek, The Netherlands.
Stem Cells. 1994 Jul;12(4):402-8. doi: 10.1002/stem.5530120407.
The systemic treatment of soft tissue sarcomas is difficult due to the limited availability of active cytotoxic drugs. Combinations of cytotoxic drugs at standard doses do increase toxicity but do not improve response rates or survival. All combinations are limited by myelosuppression, mainly leukocytopenia. For at least two of the four active drugs (doxorubicin and ifosfamide) studies have shown a clear dose-response relationship. Recent studies have focused on increasing dose-intensity by increasing dosages or shortening treatment intervals, which is only possible by the use of hematological growth factors. This review will focus on the latter concept.
